NurOwn, phase 2, randomized, clinical trial in patients with ALS
Top Cited Papers
Open Access
- 10 December 2019
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 93 (24), e2294-e2305
- https://doi.org/10.1212/wnl.0000000000008620
Abstract
Objective To determine the safety and efficacy of mesenchymal stem cell (MSC)-neurotrophic factor (NTF) cells (NurOwn®, autologous bone marrow-derived MSCs, induced to secrete NTFs) delivered by combined intrathecal and intramuscular administration to participants with amyotrophic lateral sclerosis (ALS) in a phase 2 randomized controlled trial. Methods The study enrolled 48 participants randomized 3:1 (treatment: placebo). After a 3-month pretransplant period, participants received 1 dose of MSC-NTF cells (n = 36) or placebo (n = 12) and were followed for 6 months. CSF was collected before and 2 weeks after transplantation. Results The study met its primary safety endpoint. The rate of disease progression (Revised ALS Functional Rating Scale [ALSFRS-R] slope change) in the overall study population was similar in treated and placebo participants. In a prespecified rapid progressor subgroup (n = 21), rate of disease progression was improved at early time points (p < 0.05). To address heterogeneity, a responder analysis showed that a higher proportion of treated participants experienced ≥1.5 points/month ALSFRS-R slope improvement compared to placebo at all time points, and was significant in rapid progressors at 4 and 12 weeks (p = 0.004 and 0.046, respectively). CSF neurotrophic factors increased and CSF inflammatory biomarkers decreased in treated participants (p < 0.05) post-transplantation. CSF monocyte chemoattractant protein-1 levels correlated with ALSFRS-R slope improvement up to 24 weeks (p < 0.05). Conclusion A single-dose transplantation of MSC-NTF cells is safe and demonstrated early promising signs of efficacy. This establishes a clear path forward for a multidose randomized clinical trial of intrathecal autologous MSC-NTF cell transplantation in ALS. Classification of evidence This phase II study provides Class I evidence.Keywords
This publication has 24 references indexed in Scilit:
- Targeting miR‐155 restores abnormal microglia and attenuates disease in SOD1 miceAnnals of Neurology, 2014
- Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implicationsNature Immunology, 2014
- Safety of repeated transplantations of neurotrophic factors‐secreting human mesenchymal stromal stem cellsClinical and Translational Medicine, 2014
- Downregulation of MicroRNA-9 in iPSC-Derived Neurons of FTD/ALS Patients with TDP-43 MutationsPLOS ONE, 2013
- Isoalantolactone Inhibits UM-SCC-10A Cell Growth via Cell Cycle Arrest and Apoptosis InductionPLOS ONE, 2013
- Immune-mediated Mechanisms in the Pathoprogression of Amyotrophic Lateral SclerosisJournal of Neuroimmune Pharmacology, 2013
- Amyotrophic lateral sclerosisThe Lancet, 2011
- Clinical significance in the change of decline in ALSFRS-RAmyotrophic Lateral Sclerosis, 2010
- Mesenchymal stem cells in health and diseaseNature Reviews Immunology, 2008
- MicroRNAs: Genomics, Biogenesis, Mechanism, and FunctionCell, 2004